Pedro Miguel Alves

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

Jean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer et al. · Journal of Thoracic Oncology · 2016 · 87 citations · Full text

Medicine, Immunology, Oncology +17

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

Ralf Gutzmer, Licia Rivoltini, E. Levchenko et al. · ESMO Open · 2016 · 74 citations · Full text

Medicine, Immunology, Oncology +15

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer

Giuseppe Curigliano, Gilles Romieu, Mario Campone et al. · Breast Cancer Research and Treatment · 2016 · 44 citations

Medicine, Immunology, Oncology +16

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Steven Limentani, Mario Campone, Thierry Dorval et al. · Breast Cancer Research and Treatment · 2016 · 30 citations · Full text

Medicine, Immunology, Oncology +17

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

M. Higgins, Giuseppe Curigliano, Véronique Dièras et al. · Breast Cancer Research and Treatment · 2017 · 24 citations · Full text

Medicine, Immunology, Oncology +17